D.A. Davidson & CO. Takes $202,000 Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

D.A. Davidson & CO. purchased a new position in ADMA Biologics, Inc. (NASDAQ:ADMA) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 11,760 shares of the biotechnology company’s stock, valued at approximately $202,000.

Several other large investors also recently modified their holdings of the company. State Street Corp lifted its holdings in ADMA Biologics by 61.4% in the third quarter. State Street Corp now owns 13,004,993 shares of the biotechnology company’s stock valued at $259,970,000 after acquiring an additional 4,945,063 shares during the period. Perpetual Ltd bought a new position in shares of ADMA Biologics in the 4th quarter worth approximately $62,300,000. Lord Abbett & CO. LLC bought a new position in shares of ADMA Biologics in the 3rd quarter worth approximately $61,858,000. Allspring Global Investments Holdings LLC boosted its holdings in shares of ADMA Biologics by 1,144.4% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 2,841,849 shares of the biotechnology company’s stock worth $51,016,000 after buying an additional 2,613,482 shares during the last quarter. Finally, Principal Financial Group Inc. grew its position in ADMA Biologics by 785.7% during the third quarter. Principal Financial Group Inc. now owns 1,194,221 shares of the biotechnology company’s stock valued at $23,872,000 after buying an additional 1,059,394 shares during the period. Institutional investors own 75.68% of the company’s stock.

ADMA Biologics Stock Performance

Shares of NASDAQ ADMA opened at $15.44 on Friday. The stock has a market cap of $3.65 billion, a PE ratio of 55.14 and a beta of 0.75. ADMA Biologics, Inc. has a 1 year low of $5.08 and a 1 year high of $23.64. The firm has a fifty day moving average price of $16.80 and a 200-day moving average price of $18.00. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on ADMA shares. HC Wainwright increased their price target on shares of ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday, November 8th. Raymond James raised their target price on ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a report on Friday, November 8th.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.